Immuneering Corporation announced on August 25, 2025, a clinical supply agreement with Eli Lilly and Company. This agreement will facilitate the evaluation of Immuneering’s lead product candidate, atebimetinib (IMM-1-104), in combination with Lilly’s second-generation KRAS G12C inhibitor, olomorasib (LY3537982).
The collaboration supports a planned Phase 2 clinical trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy. Preclinical studies of this combination demonstrated enhanced tumor regression, delayed emergence of tumor resistance, and prolonged survival compared to monotherapy.
This marks Immuneering's second such collaboration this year, following an agreement with Regeneron Pharmaceuticals in February 2025. Immuneering will retain global development and commercialization rights to atebimetinib, positioning the company to explore a pan-MAPK solution in challenging tumor types like NSCLC.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.